Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial Responses (PR) 75% Overall Response rate (ORR): 6 total CR and ...

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

You can vote once per day, every day until July 31st for who you’d like to see in the final round. The winner will not only ...

This Sunday, more than 15,000 enthusiastic runners will take to the streets of London for the annual Saucony London 10k — an ...

Half Year ReportHeidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business 10.07.2025 / 07:03 CET/CESTThe issuer is solely responsible for the content of this ...

Peter Cole, 81, sat inside the club’s executive suite with tickets generously donated by Scottish Power. Peter Cole and ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

Treatment for non-Hodgkin lymphoma can depend on the type and stage. Learn more here.